Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
FLAC Stock Forecast 2026-2027
$33.28
Current Price
$475.94M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to FLAC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
FLAC Price Momentum
-10.0%
1 Week Change
+9.5%
1 Month Change
+50.1%
1 Year Change
-5.1%
Year-to-Date Change
-21.1%
From 52W High of $42.21
+62.1%
From 52W Low of $20.53
📊 TOP ANALYST CALLS
Did FLAC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Frazier Lifesciences is one of their latest high-conviction picks.
Latest FLAC Stock Price Targets & Analyst Predictions
FLAC has shown a year-to-date change of -5.1% and a 1-year change of 50.1%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for FLAC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FLAC Analyst Ratings
0
Buy
0
Hold
0
Sell
FLAC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $33.28
Latest FLAC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FLAC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Frazier Lifesciences Acquisition Corporation (FLAC) Competitors
The following stocks are similar to Frazier Lifesciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
FLAC
Frazier Lifesciences
mkt cap
513.55M
Frazier Lifesciences Acquisition Corporation (FLAC) Financial Data
Valuation Metrics
Market Cap
$475.94M
Enterprise Value
$0
P/E Ratio
65.8x
PEG Ratio
N/A
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+0.1%
Current Ratio
0.5x
Debt/Equity
0.0x
ROE
+3.2%
ROA
+3.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Frazier Lifesciences Acquisition Corporation (FLAC) Business Model
About Frazier Lifesciences Acquisition Corporation
What They Do
N/A
Business Model
N/A
Additional Information
N/A
Company Information
Sector
Industry
Employees
0
CEO
Country
United States
IPO Year
2021
Frazier Lifesciences Acquisition Corporation (FLAC) Latest News & Analysis
Latest News
Quick Summary
Frazier Life Sciences has closed its Frazier Life Sciences XII fund with over $1.3 billion in commitments, focusing on early-stage biopharmaceutical investments.
Why It Matters
Frazier Life Sciences' $1.3 billion fund closing signals strong investor confidence in biopharmaceuticals, potentially driving innovation and market growth in the sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Frazier Lifesciences Acquisition Corp. completed a business combination on Nov 22, 2022, securing a $235M oversubscribed PIPE led by Frazier Healthcare and Bain Capital Life Sciences.
Why It Matters
The successful merger with Frazier Lifesciences and the substantial PIPE investment indicate strong backing and confidence in the company's growth potential, positively influencing investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Frazier Lifesciences Acquisition Corporation (FLAC) has received shareholder approval for its business combination with NewAmsterdam Pharma, a firm developing therapies for cardiometabolic diseases.
Why It Matters
The approval of the business combination signals a potential growth opportunity for FLAC, enhancing its value and attracting investor interest in the healthcare sector.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About FLAC Stock
What is Frazier Lifesciences Acquisition Corporation's (FLAC) stock forecast for 2027?
Analyst forecasts for Frazier Lifesciences Acquisition Corporation (FLAC) are not currently available. The stock is trading at $33.28.
Is FLAC stock a good investment in 2027?
Analyst ratings for FLAC are not currently available. The stock is currently trading at $33.28. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FLAC stock?
Price predictions from Wall Street analysts for FLAC are not currently available. The stock is trading at $33.28.
What is Frazier Lifesciences Acquisition Corporation's business model?
N/A
What is the highest forecasted price for FLAC Frazier Lifesciences Acquisition Corporation?
Price targets from Wall Street analysts for FLAC are not currently available. The stock is trading at $33.28.
What is the lowest forecasted price for FLAC Frazier Lifesciences Acquisition Corporation?
Price targets from Wall Street analysts for FLAC are not currently available. The stock is trading at $33.28.
What is the overall FLAC consensus from analysts for Frazier Lifesciences Acquisition Corporation?
Analyst ratings for FLAC are not currently available. The stock is trading at $33.28.
How accurate are FLAC stock price projections?
Stock price projections, including those for Frazier Lifesciences Acquisition Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 9:02 AM UTC